ESR1 and breast carcinoma: While no efficacy data of BET inhibitors in breast cancer are currently available, a combined phase I/II dose-escalation and expansion study of the BET inhibitor GSK525762 in patients with metastatic ER+ breast cancer is currently underway (ClinicalTrials.gov; NCT02964507).